Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.35 |
| ▸ | CTSL | P07711 | 2/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2383561 | 0.92 | GABRA1 (0.33) | SCN9ACTSLNR1I3CTSSKLK5 | |
| SCHEMBL2236735 | 0.92 | NR1I3 (0.37) | SCN9ACTSLNR1I3KLK5CTSK | |
| SCHEMBL2383499 | 0.91 | KLK5 (0.31) | CTSLNR1I3KLK5CTSK | |
| SCHEMBL2235865 | 0.91 | NR1I3 (0.31) | NR1I3 | |
| SCHEMBL2234791 | 0.88 | PPARG (0.33) | CTSLCTSSKLK5KCNK3 | |
| SCHEMBL2233412 | 0.79 | SCN9A (0.39) | SCN9ACTSLNR1I3KLK5CTSK | |
| SCHEMBL2237078 | 0.79 | MEN1 (0.43) | SCN9ACTSSCTSK | |
| SCHEMBL2234628 | 0.79 | MEN1 (0.43) | SCN9ACTSSCTSK | |
| SCHEMBL2382067 | 0.74 | SCN9A (0.36) | SCN9ACTSLNR1I3KLK5CTSK | |
| SCHEMBL2382110 | 0.74 | SCN9A (0.39) | SCN9ACTSLNR1I3CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2361910-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110213143-A1 | COMPOUND HAVING TAFIA INHIBITORY ACTIVITY | TAF1, TAF5, TAF11 | SCN9A 1709/4885CTSL 998/4885NR1I3 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.